Edition:
United Kingdom

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

6.74USD
21 Aug 2018
Change (% chg)

-- (--)
Prev Close
$6.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
200,703
52-wk High
$13.30
52-wk Low
$5.02

Select another date:

Tue, May 8 2018

BRIEF-Bellicum Pharmaceuticals Reports Q1 Loss Per Share Of $0.68

* BELLICUM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Bellicum Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* BELLICUM PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Bellicum Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* BELLICUM PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Bellicum Announces Clinical Hold Lifted On U.S. Studies Of BPX-501

* BELLICUM ANNOUNCES CLINICAL HOLD LIFTED ON U.S. STUDIES OF BPX-501

BRIEF-Bellicum Pharmaceuticals Reports Qtrly Loss Per Share $0.66

* BELLICUM PHARMACEUTICALS PROVIDES OPERATIONAL UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017

BRIEF-Bellicum Announces Interim Results Showing Low Rates Of Cancer Recurrence In Pediatric AML Patients Treated With BPX-501

* BELLICUM ANNOUNCES INTERIM RESULTS SHOWING LOW RATES OF CANCER RECURRENCE IN PEDIATRIC AML PATIENTS TREATED WITH BPX-501

BRIEF-Bellicum Pharma Says Effective Feb 20, Board Approved Increase In Size Of Board To 8 Members

* BELLICUM PHARMA SAYS EFFECTIVE FEB 20, BOARD APPROVED INCREASE IN SIZE OF BOARD TO 8 MEMBERS - SEC FILING Source text: (http://bit.ly/2BMB6hN) Further company coverage:

BRIEF-Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies

* BELLICUM ANNOUNCES UPDATE ON CLINICAL HOLD OF U.S. BPX-501 STUDIES

Select another date: